Amgen (AMGN) - news

• 12/13/13 : Amgen (AMGN) increases quarterly dividend ~30% to $0.61 from $0.47 per share  112.16 -0.41
• 6/13/13 3:12PM : Amgen confirms FDA approves its XGEVA (denosumab) for the treatment of giant cell tumor of bone (AMGN) 98.28 +1.91 : Co confirmed that the FDA has approved a new indication for XGEVA (denosumab) for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone (GCTB) that is unresectable or where surgical resection is likely to result in severe morbidity. The approval of XGEVA is based on positive results from two open-label trials that enrolled patients with GCTB that was either recurrent, unresectable, or for which planned surgery was likely to result in severe morbidity. The overall objective response rate of the 187 patients evaluated was 25 percent. The estimated median time to response was three months. In the 47 patients with an objective response, 51 percent (24/47) had a duration of response lasting at least eight months. Three patients experienced disease progression following an objective response. The safety profile of XGEVA in patients with GCTB was similar to that reported in studies of patients with bone metastases, and also appeared to be similar in skeletally mature adolescents and adults.